Cannabix Technologies Delivers First Breath-Based DOT-Like Multi-Drug Testing Panel for Recent-Use Detection

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing technologies is pleased to announce that it has made first commercial delivery of its new breath-based multi-drug test panel. The panel is modeled after the drug classes included in the U.S. Department of Transportation's (DOT) federally mandated urine drug testing program, including amphetamines/methamphetamines, cocaine, marijuana (THC), opiates, and phencyclidine (PCP) (the "DOT-like Panel").